Abstract 5421
Background
Nowadays, patients with Hodgkin’s lymphoma (HL) have a high cure rate. However, approximately 20% pts have relapse or progressive disease. The main histological feature in HL is presence by Hodgkin Reed-Sternberg (HRS) cells. HRS cells produce a diversity of cytokines and chemokines. There is still a limited information of prognostic role expression of cytokines in patients with HL. We assessed the impact on clinical outcome of the IDO, TGF- β and IL-13 expression in patients with HL.
Methods
79 patients (pts) with HL were included in this study (median age: 41, range: 18-65 years; males: 26, females: 53). Early stages of HL have 53.3% and 46.7% pts had advanced stages. Patients were treated with ABVD or BEACOPP (14/esc) and radiation therapy. CR/PR was achieved in 86.1% of patients. 13.9% of pts had relapse or disease progression during the therapy. mRNA expression levels of IDO, TGF-β, IL-13 were measured in fresh pre-treatment tumor tissue specimens from HL patients using real-time qPCR analysis.
Results
25 pts (31.6%) had IDO positive expression (IDO+) and 54 (65.4%) pts was IDO negative (IDO-). Multivariate analysis showed that IDO+ expression correlated with worser EFS rate with HRs of 10.7 [95% confidence interval(CI) 0.4–0.6, p = 0.01], especially in 3-years EFS in IDO+ males comparing to IDO+ females (61% vs 71%, p
Conclusions
Our data showed that IDO, TGF-β and IL13 expressions have a role in predicting clinical outcome in pts with HL. Positive expression of IDO, TGF-β and high expression level of IL13 could be considered as a negative prognostic marker. Significantly worser outcome had pts with positive expression of two cytokines comparing with patients, who had only one positive marker.
Clinical trial identification
Legal entity responsible for the study
T. Skrypets
Funding
None
Disclosure
All authors have declared no conflicts of interest.